Immune Design Corp is a privately held biotechnology company based in Seattle, WA. IDC brings together some of the world’s leaders in the field of molecular immunology to develop vaccines for the prevention and treatment of infectious and malignant disease. The company employs leading edge technologies to target and activate dendritic cells for effective antigen presentation to direct the desired immune response. For more information, go to xxx.xxxxxxxxxxxx.xxx. *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. About MedImmune: MedImmune, the worldwide biologics unit for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at xxx.xxxxxxxxx.xxx. Media Relations: Immune Design Corp. Xxxxxx X. Xxxxxxxxx (000) 000-0000 xxxxx@xxxxxxxxxxxx.xxx *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXHIBIT E Chemical Structure of Glucopyranosyl Lipid Adjuvant *** *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. APPENDIX I (***)
Immune Design Corp. By: /s/ Xxxxxx Xxxx Xxxxxx Xxxx, Chief Executive Officer I have read, understand and agree fully to the foregoing Agreement: /s/ Xxxxxxx X. Xxxxxx 28 June 2016 Xxxxxxx X. Xxxxxx, M.D. Date Exhibit A SEPARATION DATE RELEASE (To be signed and returned to the Company on the Separation Date) In exchange for the severance benefits to be provided to me by Immune Design Corp. (the “Company”) pursuant to the transition agreement between the Company and me dated June 23, 2016 (the “Agreement”), I hereby provide the following Separation Date Release (the “Release”). In exchange for the consideration under the Agreement to which I would not otherwise be entitled, I hereby generally and completely release the Company and its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent or subsidiary entities, insurers, affiliates and assigns from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions prior to or on the date I sign this Release. This release includes, but is not limited to: (1) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (2) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options or any other ownership interests in the Company; (3) all claims for breach of contract, wrongful termination or breach of the implied covenant of good faith and fair dealing; (4) all tort claims, including claims for fraud, defamation, emotional distress and discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act (the “ADEA”) (as amended), or the California Fair Employment and Housing Act (as amended). Notwithstanding the foregoing, I am not hereby releasing the Company from any of the following claims (collectively, the “Excluded Claims”): (a) any rights or claims for indemnification I may have pursuant to any written indemnification agreement with the Company to which I am a party, the charter, bylaws, or operating ag...
